ArticleOpen forum infectious diseases2020
Out of Sight-Out of Mind: Impact of Cascade Reporting on Antimicrobial Usage.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Antimicrobial stewardship strategies for implementing the 2019 EUCAST "I" definition.BMC infectious diseases · 2025Article
- Point-Counterpoint: Cascade reporting-useful tool to support antimicrobial stewardship, or dangerously misleading.Journal of clinical microbiology · 2025Review
- Observational
- A quasi-experimental study of a bundled diagnostic stewardship intervention for ventilator-associated pneumonia.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Article
- The importance of pharmacist engagement in diagnostic stewardship.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Implementing diagnostic stewardship to improve diagnosis of urinary tract infections across three medical centers: A qualitative assessment.Infection control and hospital epidemiology · 2023Article
- Antimicrobial Stewardship Techniques for Critically Ill Patients with Pneumonia.Antibiotics (Basel, Switzerland) · 2023Review
- Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital.Antimicrobial resistance and infection control · 2022Observational
- What's New in Antibiograms? Updating CLSI M39 Guidance with Current Trends.Journal of clinical microbiology · 2022Review
- New definitions of susceptibility categories EUCAST 2019: clinic application.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Effects of cascade reporting of susceptibility profiles for Enterobacterales on broad-spectrum antibiotics use and resistance.European journal of hospital pharmacy : science and practice · 2022Article
- Impact of cascade reporting of antimicrobial susceptibility on fluoroquinolone and meropenem consumption at a Veterans' Affairs medical center.Infection control and hospital epidemiology · 2022Article
- Impact of fluoroquinolone cascade reporting of urine samples on antibiotic prescribing rates in a network of urgent care clinics.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Quality Improvement Interventions and Implementation Strategies for Urine Culture Stewardship in the Acute Care Setting: Advances and Challenges.Current infectious disease reports · 2021Article
- Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam forInfection control and hospital epidemiology · 2021Article
- The Need for Dedicated Microbiology Leadership in the Clinical Microbiology Laboratory.Journal of clinical microbiology · 2021Article
- A Case Series of Diarrheal Diseases Associated withInfectious disease reports · 2021Article
- Purposeful microbiology comment added to urine cultures withAccess microbiology · 2021Article
- Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy.Current infectious disease reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a paucity of data evaluating the strategy of suppressing broader-spectrum antibiotic susceptibilities on utilization. Cascade reporting (CR) is a strategy of reporting antimicrobial susceptibility test results in which secondary (eg, broader-spectrum, costlier) agents may only be reported if an organism is resistant to primary agents within a particular drug class. Our objective was to evaluate the impact of ceftriaxone-based cascade reporting on utilization of cefepime and clinical outcomes in patients with ceftriaxone-susceptible
methodsWe compared post-CR (July 2014-June 2015) with baseline (July 2013-June 2014), evaluating utilization of cefepime, cefazolin, ceftriaxone, ampicillin derivatives, fluoroquinolones, piperacillin/tazobactam, ertapenem, and meropenem; new
resultsMean days of therapy (DOT) among patients who received any antibiotic for cefepime decreased from 1.229 days during the baseline period to 0.813 days post-CR (adjusted relative risk, 0.668;
conclusionsIn conclusion, we demonstrated significant association of decreased cefepime utilization with the implementation of a CR based on ceftriaxone susceptibility. We demonstrated the safety of deescalation, with LOS being significantly lower during the post-CR period than in the baseline period, with no change in in-hospital mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.